TrialClinical infectious diseases : an official publication of the Infectious Diseases Society of America2026

Safety, Tolerability, and Immunogenicity of Revaccination With mRNA-1345, an mRNA Vaccine Against Respiratory Syncytial Virus, Administered 12 Months Following a Primary Dose in Adults Aged ≥50 Years.

Jaya Goswami et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.